Fort Erie, Canada

Guylaine Lepine

This inventor holds 2 USPTO granted patents. Top assignees: The UAB Research Foundation (The University of Alabama at Birmingham), University of Florida Research Foundation Inc.. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Guylaine Lepine

Introduction

Guylaine Lepine is an accomplished inventor based in Fort Erie, Canada. She has made significant contributions to the field of microbiology, particularly in the detection and prevention of periodontal disease. With a total of two patents to her name, her work has had a notable impact on health sciences.

Latest Patents

Lepine's latest patents focus on cloned Porphyromonas gingivalis genes and probes for the detection of DNA fragments from this microorganism. These fragments express proteins that elicit anti-P. gingivalis immunologic responses. Her innovations include genetically modified microorganisms that express P. gingivalis antigens. Additionally, she has developed probes, vaccines, and monoclonal antibodies aimed at the detection and prevention of periodontal disease.

Career Highlights

Throughout her career, Lepine has worked with esteemed organizations such as the University of Florida Research Foundation and the UAB Research Foundation. Her research has contributed to advancements in understanding and combating periodontal disease.

Collaborations

Some of her notable coworkers include Ann Progulske-Fox and Somying Tumwasorn, who have collaborated with her on various research projects.

Conclusion

Guylaine Lepine's innovative work in microbiology and her patents reflect her dedication to improving health outcomes related to periodontal disease. Her contributions continue to influence the field and inspire future research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…